Evidence map›Paper›PMID 34243715›Full record

ArticleBMC neurology2021

Association of serum levels of antibodies against ALDOA and FH4 with transient ischemic attack and cerebral infarction.

Hao Wang, Hao Lu, Xiao-Meng Zhang, Ken-Ichiro Goto, Eiichi Kobayashi, Yoichi Yoshida, Akihiko Adachi, Tomoo Matsutani, Yasuo Iwadate, Seiichiro Mine and 19 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC neurology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.5field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

29 authors at 9 institutions in 2 countries.

Hao Wang *Stroke Center, the First Affiliated Hospital, Jinan University, NO. 613, West Huangpu Ave., Tianhe Dist., Guangzhou, 510630, China.
Hao Lu *Stroke Center, the First Affiliated Hospital, Jinan University, NO. 613, West Huangpu Ave., Tianhe Dist., Guangzhou, 510630, China.
Xiao-Meng ZhangDepartment of Biochemistry and Genetics, Graduate School of Medicine, Chiba University, Chiba, 260-8670, Japan.
Ken-Ichiro GotoDepartment of Biochemistry and Genetics, Graduate School of Medicine, Chiba University, Chiba, 260-8670, Japan.
Eiichi KobayashiDepartment of Neurological Surgery, Graduate School of Medicine, Chiba University, Inohana 1-8-1, Chuo-ku, Chiba, 260-8670, Japan.
Yoichi YoshidaDepartment of Biochemistry and Genetics, Graduate School of Medicine, Chiba University, Chiba, 260-8670, Japan.
Akihiko AdachiDepartment of Neurological Surgery, Graduate School of Medicine, Chiba University, Inohana 1-8-1, Chuo-ku, Chiba, 260-8670, Japan.
Tomoo MatsutaniDepartment of Neurological Surgery, Graduate School of Medicine, Chiba University, Inohana 1-8-1, Chuo-ku, Chiba, 260-8670, Japan.
Yasuo IwadateDepartment of Neurological Surgery, Graduate School of Medicine, Chiba University, Inohana 1-8-1, Chuo-ku, Chiba, 260-8670, Japan.
Seiichiro MineDepartment of Neurological Surgery, Graduate School of Medicine, Chiba University, Inohana 1-8-1, Chuo-ku, Chiba, 260-8670, Japan.
Toshio MachidaDepartment of Neurological Surgery, Chiba Cerebral and Cardiovascular Center, Chiba, 290-0512, Japan.
Mizuki SataDepartment of Public Health, Social Department of Social and Environmental Medicine, Graduate School of Medicine, Osaka University, Suita, Japan.
Kazumasa YamagishiDepartment of Public Health Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan.
Hiroyasu IsoDepartment of Public Health, Social Department of Social and Environmental Medicine, Graduate School of Medicine, Osaka University, Suita, Japan.
Norie SawadaEpidemiology and Prevention Group, Center for Public Health Sciences, National Cancer Center, Tokyo, Japan.
Shoichiro TsuganeEpidemiology and Prevention Group, Center for Public Health Sciences, National Cancer Center, Tokyo, Japan.
Ikuo KamitsukasaDepartment of Neurology, Chiba Rosai Hospital, Chiba, 290-0003, Japan.
Takeshi WadaDepartment of Internal Medicine, Chiba Aoba Municipal Hospital, Chiba, 260-0852, Japan.
Akiyo AotsukaDepartment of Internal Medicine, Chiba Aoba Municipal Hospital, Chiba, 260-0852, Japan.
Kazuo SugimotoDepartment of Biochemistry and Genetics, Graduate School of Medicine, Chiba University, Chiba, 260-8670, Japan.
Hirotaka TakizawaPort Square Kashiwado Clinic, Kashiwado Memorial Foundation, Chiba, 260-0025, Japan.
Koichi KashiwadoDepartment of Neurology, Kashiwado Hospital, Chiba, 260-0854, Japan.
Hideo ShinDepartment of Neurosurgery, Higashi Funabashi Hospital, Chiba, 274-0065, Japan.
Go TomiyoshiDepartment of Biochemistry and Genetics, Graduate School of Medicine, Chiba University, Chiba, 260-8670, Japan.
Rika NakamuraDepartment of Biochemistry and Genetics, Graduate School of Medicine, Chiba University, Chiba, 260-8670, Japan.
Natsuko ShinmenDepartment of Biochemistry and Genetics, Graduate School of Medicine, Chiba University, Chiba, 260-8670, Japan.
Hideyuki KurodaMedical Project Division, Research Development Center, Fujikura Kasei Co., Saitama, 340-0203, Japan.
Anding XuStroke Center, the First Affiliated Hospital, Jinan University, NO. 613, West Huangpu Ave., Tianhe Dist., Guangzhou, 510630, China. tlil@jnu.edu.cn.
Takaki HiwasaDepartment of Biochemistry and Genetics, Graduate School of Medicine, Chiba University, Chiba, 260-8670, Japan. hiwasa_takaki@faculty.chiba-u.jp.ORCID http://orcid.org/0000-0002-0475-3881
Chiba University · JPChiba Aoba Municipal Hospital · JPFirst Affiliated Hospital of Jinan University · CNThe University of Osaka · JPChiba Cerebral and Cardiovascular Center · JPChibaken Saiseikai Narashino Hospital · JPFujikura (Japan) · JPFunabashi Orthopaedic Hospital · JPUniversity of Tsukuba · JP

Funding

Ministry of Health, Labour and Welfare and Ministry of Education, Culture, Sports, Science and Technology (MEXT) 17K16626Ministry of Health, Labour and Welfare and Ministry of Education, Culture, Sports, Science and Technology (MEXT) 20K17953Ministry of Health, Labour and Welfare of Japan 17K19810Ministry of Health, Labour and Welfare of Japan 19K09451Ministry of Health, Labour and Welfare of Japan Grant-in-Aid for Cancer ResearchNatural Science Foundation of Guangdong Province 2018A0303131003Science and Technology Program of Guangzhou 201707010449
6 · The paper itself

Abstract

backgroundIschemic stroke, including transient ischemic attack (TIA) and acute-phase cerebral infarction (aCI), is a serious health problem in the aging society. Thus, this study aimed to identify TIA and aCI biomarkers.

methodsIn 19 patients with TIA, candidate antigens recognized by serum IgG autoantibodies were screened using a human aortic endothelial cell cDNA library. Through amplified luminescent proximity homogeneous assay-linked immunosorbent assay (AlphaLISA), serum antibody levels against the candidate antigens were examined in healthy donor (HD), TIA, and aCI cohorts (n = 285, 92, and 529). The plasma antibody levels in the Japan Public Health Center-based Prospective Cohort Study (1991-1993) were also examined.

resultsThe candidate antigens were aldolase A (ALDOA) and fumarate hydratase (FH). In AlphaLISA, patients with TIA or aCI had higher anti-ALDOA antibody (ALDOA-Ab) and anti-FH antibody (FH-Ab) levels than the HDs (P < 0.05). In a multivariate logistic regression analysis, the ALDOA-Ab (odds ratio [OR]: 2.46, P = 0.0050) and FH-Ab (OR: 2.49, P = 0.0037) levels were independent predictors of TIA. According to the case-control study, the ALDOA-Ab (OR: 2.50, P < 0.01) and FH-Ab (OR: 2.60, P < 0.01) levels were associated with aCI risk. In a correlation analysis, both ALDOA-Abs and FH-Abs were well associated with hypertension, coronary heart disease, and habitual smoking. These antibody levels also correlated well with maximum intima-media thickness, which reflects atherosclerotic stenosis.

conclusionsALDOA-Abs and FH-Abs can be novel potential biomarkers for predicting atherosclerotic TIA and aCI.

Indexed as

Cerebral InfarctionIschemic Attack, TransientAutoantibodiesBiomarkersCase-Control StudiesFructose-Bisphosphate AldolaseHumansALDOA protein, humanAutoantibodiesBiomarkersFructose-Bisphosphate AldolaseALDOAAntibody biomarkerCerebral infarctionFHTransient ischemic attack

Identifiers

PMID34243715
PMCPMC8268454
OpenAlexW3118754945

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.